Skip to main content

Life Science Instrumentation Market Set to Soar Past USD 107.34 Billion by 2030 | Skyquest Technology

Exploring the life science instrumentation landscape reveals a diverse array of technologies, including PCR, spectroscopy, microscopy, chromatography, electrophoresis, NGS, flow cytometry, and centrifuges. These innovative tools find applications in clinical diagnostics, research, and beyond, with various distribution channels such as hospitals, diagnostic labs, pharmaceuticals, biotech firms, academia, and research institutions. As we forecast the industry from 2023 to 2030, we anticipate significant growth in this dynamic sector.

Westford, USA, Aug. 28, 2023 (GLOBE NEWSWIRE) — The global Life Science Instrumentation market size is expected to reach USD 107.34 billion by 2030 and exhibit a CAGR of 6.5% in the forecast period (2023−2030), according to Skyquest’s latest research report. The advancements and innovations, growing research and development activities in life sciences, increasing demand for personalized medicine, rising emphasis on drug discovery and development, expanding biotechnology and pharmaceutical industries, growing prevalence of chronic diseases, supportive government initiatives and funding for life science research, rising collaborations between academic institutions and industry players, increasing focus on proteomics and genomics research, demand for high-throughput screening techniques, growing importance of diagnostics in healthcare, adoption of automation and robotics in laboratories, and expanding applications of life science technologies in agriculture and environmental studies are fueling the market’s growth.

According to SkyQuest’s latest global research of the Life Science Instrumentation market,  increasing integration of artificial intelligence and machine learning, growing focus on single-cell analysis techniques, rise of multi-omics approaches in research, surging demand for portable and point-of-care instruments, expanding use of lab automation solutions, emergence of lab-on-a-chip technologies, advancing 3D cell culture techniques, adoption of high-content screening methods, utilization of CRISPR technology for gene editing applications, expanding use of spectroscopy techniques in life sciences, integration of big data analytics for complex data interpretation, and rising sustainability initiatives in instrument design and manufacturing are the trends that aid in the market’s growth.

Get a sample copy of this report:

https://www.skyquestt.com/sample-request/life-science-instrumentation-market

Browse in-depth TOC on “Life Science Instrumentation Market”

  • Pages – 157
  • Tables – 101
  • Figures -76

Life science instrumentation is the use of equipment and instruments to study living organisms and their functions. These instruments are used in a variety of applications, including research, diagnostics, and pharmaceutical development.

Prominent Players in Life Science Instrumentation Market

  • Agilent Technologies
  • Danaher
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • PerkinElmer
  • Roche Diagnostics
  • Illumina
  • GE Healthcare
  • Shimadzu
  • Bruker
  • Waters Corporation
  • Sartorius
  • Eppendorf
  • Promega
  • Qiagen
  • BioTek Instruments
  • Tecan
  • Hamilton Company
  • VWR International
  • Merck KGaA
  • Lonza Group
  • QIAGEN

Report Scope & Segmentation:

Attributes

 

Details

 

Forecast Period

 

2023-2030
Market Size in 2022

 

 72.85 Billion
2030 Value Projection

 

107.34 Billion
CAGR 6.5%
Segments Covered

 

 

 

 

  • Technology

PCR, Spectroscopy, Microscopy, Chromatography, Electrophoresis, Next- Generation Sequencing (NGS), Flow Cytometry, Centrifuges, Others

  • Application

Clinical, Diagnostic, Research, Others

  • Distribution Channel

Hospitals, Diagnostic Laboratories, Pharmaceutical, Biotechnology Companies, Academic, Research Institutions, Others

 

 

 

Regions Covered

 

 

North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)

Next-Generation Sequencing (NGS) Demand to Grow Substantially in the Forecast Period

Next-Generation Sequencing (NGS) dominated the global online market as it allows for the simultaneous sequencing of thousands to millions of DNA fragments, enabling researchers to generate massive amounts of data in a relatively short time compared to traditional methods.

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/life-science-instrumentation-market

Drug Discovery and Development are the Leading Application Segment

In terms of application, drug discovery and development are the leading segment as pharmaceutical and biotechnology industries continually research and develop new drugs to address a wide range of diseases. This sustained R&D effort demands advanced instrumentation to accelerate the drug discovery process.

North America is the leading Market Due to the Technological Advancements.

Region-wise, North America is one of the largest growing markets with a huge emphasis on technological advancements. The region has a well-established and robust research infrastructure with numerous renowned academic institutions, research centers, and biotechnology hubs. This fosters a conducive environment for the adoption of advanced life science instrumentation..

A recent report thoroughly analyzes the major players operating within the Life Science Instrumentation market. This comprehensive evaluation has considered several crucial factors, such as collaborations, mergers, innovative business policies, and strategies, providing invaluable insights into the key trends and breakthroughs in the market. Additionally, the report has carefully scrutinized the market share of the top segments and presented a detailed geographic analysis. Finally, the report has highlighted the major players in the industry and their ongoing endeavours to develop innovative solutions that cater to the ever-increasing demand for Life Science Instrumentation.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/life-science-instrumentation-market

Key Developments in Life Science Instrumentation Market

  • In February 2023, Nova Metrix LLC acquired Vallen Systeme, a German manufacturer of monitoring systems. This acquisition added Vallen Systeme’s expertise in acoustic emission and Life Science Instrumentation technologies to Nova Metrix’s product offerings.
  • In March 2023, Hottinger Baldwin Messtechnik GmbH acquired Digitexx Data Systems, Inc., a leading provider of data acquisition and processing systems for SHM applications. This acquisition strengthened Hottinger Baldwin Messtechnik GmbH’s position in the SHM market and expanded its portfolio of data acquisition and processing solutions.

Key Questions Answered in Life Science Instrumentation Market Report

  • What specific growth drivers will impact the market during the forecast period?
  • Can you list the top companies in the market and explain how they have achieved their positions of influence?
  • In what ways do regional trends and patterns differ within the global market, and how might these differences shape the market’s future growth?

Related Reports in SkyQuest’s Library:

Global Indwelling Catheters Market

Global Continuous Glucose Monitoring Devices Market

Global Vagus Nerve Stimulation Market

Global Endometrial Ablation Market

Global Artificial Disc Replacement Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

LinkedIn Facebook Twitter

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.